• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Citius Pharmaceuticals Inc.

    11/27/24 4:05:31 PM ET
    $CTXR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTXR alert in real time by email
    SC 13D/A 1 ea0222889-13da2mazur_citius.htm AMENDMENT NO. 2 TO SCHEDULE 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13D

    (Amendment No. 2)*

     

    Under the Securities Exchange Act of 1934

     

     

     

    CITIUS PHARMACEUTICALS, INC.

    (Name of Issuer)

     

     

     

    Common Stock, $0.001 Par Value

    (Title of Class of Securities)

     

    17322U306

    (CUSIP Number)

     

    Leonard L. Mazur

    11 Commerce Drive, 1st Floor

    Cranford, New Jersey 07016

    (908) 967-6676

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    November 25, 2024

    (Date of Event which Requires Filing of this Statement)

     

     

     

    If the filing person has previously filed a statement on Schedule l3G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 17322U306

    Page 2 of 4

     

    1.

    Name of Reporting Person

    I.R.S. Identification No. of Above Person (Entities Only)

     

    Leonard L. Mazur

    2.

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

    Not Applicable

    3.

    SEC Use Only

     

    4.

    Source of Funds (See Instructions)

     

    Not Applicable

    5.

    Check if Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e)

     

    Not Applicable

    6.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned By

    Each Reporting

    Person With

    7.

    Sole Voting Power

     

    754,295(1) (2) (3)

    8.

    Shared Voting Power

     

    0

    9.

    Sole Dispositive Power

     

    754,295(1) (2) (3)

    10.

    Shared Dispositive Power

     

    0

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    754,295

    12.

    Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares

     

    ☐

    13.

    Percent of Class Represented by Amount in Row (11)

     

    9.3%(3)

    14.

    Type of Reporting Person

     

    IN

     

     

    (1)Beneficial ownership numbers reflect the Reverse Stock Split effective November 25, 2024. See Explanatory Note.

     

    (2)Includes as of November 25, 2024, (i) 261,481 shares of Common Stock, par value $0.001 per share (the “Common Stock”) of Citius Pharmaceuticals, Inc. (the “Issuer”) issuable upon the exercise of currently exercisable warrants, and (ii) 82,600 shares of Common Stock subject to options held by Leonard L. Mazur (the “Reporting Person”) that are exercisable within 60 days of November 25, 2024. The reporting Person holds options to purchase up to an aggerate of 46,000 shares of Common Stock that are not exercisable within 60 days of November 25, 2024.

     

    (3)The calculation is based on 7,727,243 shares of Common Stock of the Issuer outstanding as of November 25, 2024, as disclosed by the Issuer to the Reporting Person, giving effect to the Reverse Stock Split.

     

     

     

     

    CUSIP No. 17322U306

    Page 3 of 4

     

    EXPLANATORY NOTE

     

    On November 25, 2024, at 5:00 pm Eastern Time, the Issuer effected a 1-for-25 reverse stock split of its common stock (the “Reverse Stock Split”). The Issuer’s common stock began trading on the Nasdaq Capital Market on a split-adjusted basis beginning upon market open on November 26, 2024

     

    This Amendment No. 2 (“Amendment No. 2”) to the Schedule 13D of the Reporting Person filed on August 27, 2108, as amended by Amendment No. 1 filed on February 18, 2022, amends and supplements the Schedule 13D as specifically set forth herein, to give effect to the Reverse Stock Split. In connection with the Reverse Stock Split, the Issuer’s Common Stock was issued a new CUSIP number of 17322U306.

     

    Item 3.Source and Amount of Funds or Other Consideration.

     

    Item 3 is hereby amended to add the following:

     

    On October 4, 2022, the Reporting Person was granted an option to purchase 22,000 shares of Common Stock of the Issuer at a purchase price of $31.25 per share. One third of the options vest on the first, second and third anniversary of the grant date of October 4, 2022.

     

    On October 10, 2023, the Reporting Person was granted an option to purchase 22,000 shares of Common Stock of the Issuer at a purchase price of $17.50 per share. One third of the options vest on the first, second and third anniversary of the grant date of October 10, 2023.

     

    On November 7, 2024, the Reporting Person was granted an option to purchase 24,000 shares of Common Stock of the Issuer at a purchase price of $9.50 per share. One third of the options vest on the first, second and third anniversary of the grant date of November 7, 2024.

     

    Item 5.Interest in Securities of the Issuer.

     

    Item 5 is hereby amended to add the following:

     

    (a)

     

    The Reporting Person is the beneficial owner of an aggregate of 754,295 shares of the Issuer’s Common Stock, which represents approximately 9.3% of the Issuer’s outstanding Common Stock, based upon 7,727,243 shares of Common Stock outstanding as of November 25, 2024, as disclosed by the Issuer to the Reporting Person, giving effect to the Reverse Stock Split.

     

    The Reporting Person’s beneficial ownership consists of (i) 410,214 shares of the Issuer’s Common Stock, (ii) 261,481 shares of the Issuer’s Common Stock issuable upon the exercise of warrants, and (iii) 82,600 shares of the Issuer’s Common Stock subject to options held by the Reporting Person that are exercisable within 60 days of November 25, 2024. The reporting Person holds options to purchase up to an aggerate of 46,000 shares of Common Stock that are not exercisable within 60 days of November 25, 2024.

     

    (b)

     

    The Reporting Person has sole voting and dispositive power of 754,295 shares of the Issuer’s Common Stock beneficially owned.

     

     

     

     

    CUSIP No. 17322U306

    Page 4 of 4

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 27, 2024  
       
      /s/ Leonard L. Mazur
      Leonard L. Mazur

     

     

     

     

    Get the next $CTXR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CTXR

    DatePrice TargetRatingAnalyst
    12/30/2024$9.00Hold → Buy
    D. Boral Capital
    1/18/2022$4.00 → $6.00Buy
    HC Wainwright & Co.
    11/30/2021$4.00Buy
    Maxim Group
    More analyst ratings

    $CTXR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Webb Carol

      4 - Citius Pharmaceuticals, Inc. (0001506251) (Issuer)

      11/12/24 5:00:31 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Dutia Suren G

      4 - Citius Pharmaceuticals, Inc. (0001506251) (Issuer)

      11/12/24 5:00:22 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Vice Chairman Holubiak Myron Z

      4 - Citius Pharmaceuticals, Inc. (0001506251) (Issuer)

      11/12/24 5:00:18 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTXR
    SEC Filings

    See more
    • Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Citius Pharmaceuticals, Inc. (0001506251) (Filer)

      6/12/25 8:45:29 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Citius Pharmaceuticals Inc.

      424B5 - Citius Pharmaceuticals, Inc. (0001506251) (Filer)

      6/11/25 8:00:15 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Citius Pharmaceuticals, Inc. (0001506251) (Filer)

      6/9/25 5:29:24 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTXR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025

      CRANFORD, N.J., June 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced that preparations for the commercial launch of LYMPHIR™, an FDA-approved immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), are nearing completion. The Company believes it is now operationally positioned to transition from a development-stage enterprise to a fully integrated commercial organization, with all major launch-enabling activities underway. Final preparations are in process for a U.S. launch of LYMPHIR in the second h

      6/17/25 8:08:00 AM ET
      $CTOR
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • After Major Oncology Conference, All Eyes Turn to Industry Innovation

      USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

      6/12/25 9:00:00 AM ET
      $CAH
      $CTOR
      $CTXR
      $ONCY
      Other Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

      $6 million upfront with up to an additional $9.8 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants CRANFORD, N.J., June 12, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (NASDAQ:CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase of an aggregate of 4,920,000 shares of its common stock  (or pre-funded warrants in lieu thereof) and accompanying short-term warrants to purchase up to an aggregate of 9,

      6/12/25 8:35:00 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTXR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citius Pharmaceuticals upgraded by D. Boral Capital with a new price target

      D. Boral Capital upgraded Citius Pharmaceuticals from Hold to Buy and set a new price target of $9.00

      12/30/24 7:26:29 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Citius Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Citius Pharmaceuticals with a rating of Buy and set a new price target of $6.00 from $4.00 previously

      1/18/22 10:01:19 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on Citius Pharmaceuticals with a new price target

      Maxim Group initiated coverage of Citius Pharmaceuticals with a rating of Buy and set a new price target of $4.00

      11/30/21 8:45:24 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTXR
    Financials

    Live finance-specific insights

    See more
    • Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

      Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024. Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIR™ (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL);Advanced ma

      12/27/24 5:00:00 PM ET
      $CTOR
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments

      Management call scheduled for Tuesday, August 13, 2024, at 8:30 AM ET CRANFORD, N.J., Aug. 12, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), today announced that it will host an investor call on Tuesday, August 13, 2024 at 8:30 am ET to discuss recent and upcoming developments. Citius Chairman and CEO, Leonard Mazur, will be joined by members of the management team. A question and answer period will follow management's discussion. Conference Call Details: Date: Tuesday, August 13, 2024 Time: 8:30 a.m. Eastern Time Dial In: 1-888-243-4451 (U.S. toll free) 1-412-542-4135 (international) Webcast: Register for the webcast here. A replay will

      8/12/24 8:00:00 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

      Management call scheduled for Monday, June 3, 2024 at 8:30 AM ET CRANFORD, N.J., May 29, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it will host an investor call on Monday, June 3, 2024 at 8:30 am ET to discuss the topline results of its Phase 3 Trial of Mino-Lok antibiotic lock solution. Citius Chairman and CEO, Leonard Mazur, will be joined by members of the management team to discuss the results of the Phase 3 Trial and the clinical need for Mino-Lok in patients with catheter-related blood

      5/29/24 8:30:00 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTXR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Citius Pharmaceuticals Inc.

      SC 13D/A - Citius Pharmaceuticals, Inc. (0001506251) (Subject)

      11/27/24 4:05:31 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Citius Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Citius Pharmaceuticals, Inc. (0001506251) (Subject)

      5/8/24 2:22:56 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Citius Pharmaceuticals Inc.

      SC 13G - Citius Pharmaceuticals, Inc. (0001506251) (Subject)

      1/31/24 2:08:26 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTXR
    Leadership Updates

    Live Leadership Updates

    See more
    • After Major Oncology Conference, All Eyes Turn to Industry Innovation

      USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

      6/12/25 9:00:00 AM ET
      $CAH
      $CTOR
      $CTXR
      $ONCY
      Other Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Citius Pharmaceuticals Expands Management Team with Appointment of Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls

      CRANFORD, N.J., Nov. 5, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced the appointment of pharmaceutical industry veteran Kelly Creighton, PhD as Executive Vice President of Chemistry, Manufacturing and Controls (CMC). Mr. Creighton will be responsible for the global strategic regulatory and manufacturing development plans for Citius's five pipeline programs. "With two late P

      11/5/21 9:15:00 AM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Pharmaceuticals, Inc. Announces Appointment of Ilanit Allen as Vice President, Corporate Communications and Investor Relations

      CRANFORD, N.J., May 17, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ:CTXR) today announced that Ilanit Allen has been appointed Vice President of Corporate Communications and Investor Relations, effective immediately.  In this newly created role, Ms. Allen will spearhead financial communication and investor activities, reporting to Myron Holubiak, President and Chief Executive Officer of Citius. "We are thrilled to welcome Ilanit to the Citius team as we advance our pipeline of first-in-class critical care products," stated Mr. Holubiak. "I am confident that Ilanit's extensive communications and investor relations experience, coupled with her financia

      5/17/21 12:30:00 PM ET
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care